Caligan Partners as of June 30, 2024
Portfolio Holdings for Caligan Partners
Caligan Partners holds 13 positions in its portfolio as reported in the June 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Liquidia Corporation Com New (LQDA) | 29.0 | $124M | 10M | 12.00 | |
Alimera Sciences Com New | 21.9 | $94M | 17M | 5.56 | |
Anika Therapeutics (ANIK) | 8.5 | $36M | 1.4M | 25.33 | |
Exelixis (EXEL) | 8.0 | $34M | 1.5M | 22.47 | |
BioCryst Pharmaceuticals (BCRX) | 6.6 | $28M | 4.6M | 6.18 | |
Verona Pharma Sponsored Ads (VRNA) | 6.2 | $27M | 1.8M | 14.46 | |
Evolus (EOLS) | 5.5 | $24M | 2.2M | 10.85 | |
Agios Pharmaceuticals (AGIO) | 5.2 | $22M | 515k | 43.12 | |
Enanta Pharmaceuticals (ENTA) | 3.2 | $14M | 1.0M | 12.97 | |
Mineralys Therapeutics (MLYS) | 2.0 | $8.7M | 746k | 11.70 | |
Y Mabs Therapeutics (YMAB) | 1.6 | $7.0M | 582k | 12.08 | |
I Mab Sponsored Ads (IMAB) | 1.3 | $5.6M | 3.4M | 1.67 | |
Outlook Therapeutics (OTLK) | 0.9 | $3.7M | 500k | 7.38 |